Aliquots - Research Briefs Archive — Page 13 of 87
-
April 26, 2022
Calculating risk for uterine fibroids
Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies. -
April 25, 2022
Molecular testing across tumor types
The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets. -
April 21, 2022
When science spills onto social media
Vanderbilt researchers report that social media posts can offer insights into how the public feels about genome editing, with stances varying across platforms and differing from those of academics and policy makers. -
April 21, 2022
Youthful healing for burn wounds
Topical treatment of burns with an immunosuppressive drug counteracted the negative effects of aging on wound healing, Vanderbilt researchers have discovered. -
April 12, 2022
Financial impact of prior authorization
Prior authorization — health insurer approval of a medical intervention prior to treatment — costs more than $40 million for U.S. academic radiation oncology practices, with questionable value added to patient care. -
April 11, 2022
Peptides promote AFib arrhythmia
Peptide oligomers have detrimental metabolic effects and cause pro-arrhythmic electrophysiological changes in heart atria, suggesting they may contribute to atrial fibrillation. -
April 7, 2022
Computer eyeballs graft-vs-host disease
A machine learning algorithm identified areas of skin affected by chronic graft-versus-host disease on par with clinicians, opening the door to streamlining and standardizing this measure of patient response to therapy.